Description
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.
Cat.No
A789
Name
Itolizumab
Chemical Properties
CAS
1116433-11-4
Synonyms
ITOLIZUMAB (monoclonal antybody);Itolizumab;EQ 001;Research Grade Itolizumab(DHD87601);Research Grade Itolizumab(DHD87601);Research Grade Itolizumab(DHD87601);Research Grade Itolizumab(DHD87601);Research Grade Itolizumab(DHD87601);Itolizumab (anti-CD6);Itolizumab (anti-CD6);Itolizumab (anti-CD6);Itolizumab (anti-CD6);Itolizumab (anti-CD6);EQ-001;EQ-001;EQ-001;EQ-001;EQ-001
pH value
Corresponds to reference standard: PASS
Non-reduced CE-SDS
>95%
SEC-HPLC
>95%
Isoelectric Point
Corresponds to reference standard
Bacterial Endotoxins Test
Residual Proteins of Host Cell
Exogenous Residual DNA
Residual protein A
Biological Activity
Osmolality
Corresponds to reference standard: PASS
Peptide mapping
Corresponds to reference standard: PASS
N-terminal sequence
Corresponds to reference standard: PASS
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131Fax: +86-21-61642470Email:
Website:
